US51654W1018
© BusinessWire
10.02.2026
LTRN
LISTED
NASDAQ
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA.
More information about the...
Themefolio
Profiler
Peergroup
© BusinessWire
20.01.2026
LTRN
LISTED
NASDAQ
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarc...
Themefolio
Profiler
Peergroup
© BusinessWire
12.01.2026
LTRN
LISTED
NASDAQ
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India. This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneeri...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
03.12.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as highlights from its recent webinar. The clinical trial demonstrated e...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
13.11.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the third quarter 2025...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.11.2025
LTRN
LISTED
NASDAQ
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / November 8, 2025 / New to The Street announces the broadcast of Show Number 698, airing on Bloomberg Television this Saturday, November 8, 2025, at 6:30 PM EST, as sponsored programming.This week's show features exclusive interviews and insights from leading companies and financial professionals:Lantern P...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.11.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
News Preview
NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America's leading business television and multi-platform media brands, today announced a comprehensive media partnership with Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence company developing cancer medicines with multiple clinical-stage programs.The collab...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
LTRN
LISTED
NASDAQ
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2025 operating and financial results webcast on Thu...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
LTRN
LISTED
NASDAQ
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN)— Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, hosted by Dr. Serdar Bozdag and the newly established Center for Computational Life Sciences, brings together lea...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, today announced the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
LTRN
LISTED
NASDAQ
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 30, 2025, at 11:30 a.m. ET at th...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
LTRN
LISTED
NASDAQ
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced the successful completion of its Phase 1a clinical trial (NCT05933265) for LP-184. The trial met all primary endpoints, demonstrating a favorable safet...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
03.09.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform, today announced the successful completion of a Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting pro...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.08.2025
LTRN
LISTED
NASDAQ
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
News Preview
ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive live investor webinar with Lantern Pharma Inc. (NASDAQ:LTRN) on August 26, 2025, at 4:15 p.m. ET.The webinar will showcase how Lantern is redefini...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the second quarter 202...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites i...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors.
Dr. Schalop brings over two decades...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
News Preview
ORLANDO, FLORIDA / ACCESS Newswire / July 25, 2025 / RedChip Companies will air an interview with Lantern Pharma Inc. (Nasdaq:LTRN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Ac...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a comp...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent, expecte...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) a...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
LTRN
LISTED
NASDAQ
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern’s Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achie...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
LTRN
LISTED
NASDAQ
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today announced promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer. The resul...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
News Preview
Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
LTRN
LISTED
NASDAQ
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thu...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
LTRN
LISTED
NASDAQ
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
News Preview
Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial fo...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 3...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
LTRN
LISTED
NASDAQ
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2024 operating and financial resul...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
LTRN
LISTED
NASDAQ
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting bl...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
LTRN
LISTED
NASDAQ
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (N...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
LTRN
LISTED
NASDAQ
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative B...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
LTRN
LISTED
NASDAQ
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, today announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indic...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
LTRN
LISTED
NASDAQ
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-sma...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending Septemb...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
LTRN
LISTED
NASDAQ
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
News Preview
Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
LTRN
LISTED
NASDAQ
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thu...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
LTRN
LISTED
NASDAQ
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at t...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
LTRN
LISTED
NASDAQ
Lantern Pharma to Host & Participate in Two Public Webinars During October
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that they will be participating in and hosting two webinars that are open to the public during October.
Lantern expects to di...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
LTRN
LISTED
NASDAQ
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
LTRN
LISTED
NASDAQ
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that the company has been granted three rare pediatric disease designations (RPDD) by t...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
LTRN
LISTED
NASDAQ
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the second quarter 2024, ending June 3...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
